Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Oncolytics Biotech Inc. (ONCY)

1.93   0.08 (4.32%) 12-05 16:00
Open: 1.86 Pre. Close: 1.85
High: 2 Low: 1.86
Volume: 541,593 Market Cap: 114(M)

Technical analysis

as of: 2022-12-06 7:50:21 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.66     One year: 3.11
Support: Support1: 1.63    Support2: 1.23
Resistance: Resistance1: 2.27    Resistance2: 2.66
Pivot: 1.6
Moving Average: MA(5): 1.86     MA(20): 1.63
MA(100): 1.33     MA(250): 1.38
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 67     %D(3): 66.5
RSI: RSI(14): 62.9
52-week: High: 2.27  Low: 0.8
Average Vol(K): 3-Month: 189 (K)  10-Days: 548 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ONCY ] has closed below upper band by 12.1%. Bollinger Bands are 157.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2 - 2.01 2.01 - 2.02
Low: 1.84 - 1.85 1.85 - 1.86
Close: 1.91 - 1.93 1.93 - 1.94

Company Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Headline News

Mon, 05 Dec 2022
What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now? - Nasdaq

Fri, 02 Dec 2022
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag - Nasdaq

Fri, 02 Dec 2022
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Nasdaq

Thu, 01 Dec 2022
Healthcare Stocks Moving Thursday: VAPO, KTRA, ONCY, RMED, SQZ, BDSX, CGTX, RPID - InvestorsObserver

Thu, 01 Dec 2022
Health Care Sector Update for 12/01/2022: AZYO,NTLA,ONCY - Nasdaq

Wed, 30 Nov 2022
Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS) -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 59 (M)
Shares Float 58 (M)
% Held by Insiders 1.3 (%)
% Held by Institutions 1.3 (%)
Shares Short 115 (K)
Shares Short P.Month 161 (K)

Stock Financials

EPS -0.38
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.47
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -35.4
Return on Equity (ttm) -67.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.44
Qtrly Earnings Growth 0
Operating Cash Flow -24 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -5.19
PEG Ratio 0
Price to Book value 4.02
Price to Sales 0
Price to Cash Flow -4.8

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-05-24
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.